Skip to main content

Antiplatelet therapy: What have we learned from the ANTARCTIC trial?

Publication ,  Journal Article
Gurbel, PA; Tantry, US
Published in: Nat Rev Cardiol
November 2016

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nat Rev Cardiol

DOI

EISSN

1759-5010

Publication Date

November 2016

Volume

13

Issue

11

Start / End Page

639 / 640

Location

England

Related Subject Headings

  • Ticlopidine
  • Platelet Aggregation Inhibitors
  • Humans
  • Cardiovascular System & Hematology
  • Aspirin
  • Aged
  • Acute Coronary Syndrome
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., & Tantry, U. S. (2016). Antiplatelet therapy: What have we learned from the ANTARCTIC trial? Nat Rev Cardiol, 13(11), 639–640. https://doi.org/10.1038/nrcardio.2016.167
Gurbel, Paul A., and Udaya S. Tantry. “Antiplatelet therapy: What have we learned from the ANTARCTIC trial?Nat Rev Cardiol 13, no. 11 (November 2016): 639–40. https://doi.org/10.1038/nrcardio.2016.167.
Gurbel PA, Tantry US. Antiplatelet therapy: What have we learned from the ANTARCTIC trial? Nat Rev Cardiol. 2016 Nov;13(11):639–40.
Gurbel, Paul A., and Udaya S. Tantry. “Antiplatelet therapy: What have we learned from the ANTARCTIC trial?Nat Rev Cardiol, vol. 13, no. 11, Nov. 2016, pp. 639–40. Pubmed, doi:10.1038/nrcardio.2016.167.
Gurbel PA, Tantry US. Antiplatelet therapy: What have we learned from the ANTARCTIC trial? Nat Rev Cardiol. 2016 Nov;13(11):639–640.

Published In

Nat Rev Cardiol

DOI

EISSN

1759-5010

Publication Date

November 2016

Volume

13

Issue

11

Start / End Page

639 / 640

Location

England

Related Subject Headings

  • Ticlopidine
  • Platelet Aggregation Inhibitors
  • Humans
  • Cardiovascular System & Hematology
  • Aspirin
  • Aged
  • Acute Coronary Syndrome
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology